Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Previous work has shown that androgens inhibit breast cancer cells and tumor growth. On the other hand, androgens can be converted to mitogenic estrogens by aromatase in breast cancer cells. Here, we report that androgens, such as the aromatizable androstenedione and the non-aromatizable 5alpha-dihydrotestosterone, inhibit MCF-7 cell proliferation. This effect is observed only in the absence or at a low concentration of estrogens and is evident in cells with low aromatase activity. Growth of a new aromatase stably transfected MCF-7 cell line (Ac1) was stimulated by conversion of androstenedione into estrogens and was sensitive to aromatase inhibitors. We show that blockade of the androgen receptor (AR) in these cells by the antiandrogen casodex or by the anti-AR small interfering RNA inhibited the antiproliferative effect of dihydrotestosterone and letrozole (aromatase inhibitor). We also show that suppression of the estrogen-induced antiapoptotic protein Bcl-2 may be involved in the antiproliferative effects of androgens and letrozole. These effects can be reversed by casodex. In conclusion, the results suggest that aromatase inhibitors may exert their antiproliferative effect not only by reducing the intracellular production of estrogens but also by unmasking the inhibitory effect of androgens acting via the AR.
Macedo
Luciana F
LF
Department of Pharmacology and Experimental Therapeutics, University of Maryland, 685 West Baltimore Street, Baltimore, MD 21201, USA.
Guo
Zhiyong
Z
Tilghman
Syreeta L
SL
Sabnis
Gauri J
GJ
Qiu
Yun
Y
Brodie
Angela
A
D059002:Androgen Receptor Antagonists; D000728:Androgens / Q000494:pharmacology / Q000502:physiology*; D000735:Androstenedione / Q000494:pharmacology; D001141:Aromatase / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D048708:Cell Growth Processes / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D013196:Dihydrotestosterone / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000096:biosynthesis; D006801:Humans; D000077289:Letrozole; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D009570:Nitriles / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D034741:RNA, Small Interfering / Q000235:genetics; D011944:Receptors, Androgen / Q000096:biosynthesis; D014162:Transfection; D014230:Triazoles / Q000494:pharmacology*
D059002:Androgen Receptor Antagonists; D000728:Androgens; D047628:Estrogen Receptor alpha; D009570:Nitriles; D019253:Proto-Oncogene Proteins c-bcl-2; D034741:RNA, Small Interfering; D011944:Receptors, Androgen; D014230:Triazoles; D013196:Dihydrotestosterone; D000735:Androstenedione; D004958:Estradiol; D000077289:Letrozole; D001141:Aromatase